Safety/Effectiveness of Oral Chemokine Coreceptor 5 (CCR5) Antagonist INCB009471 in R5-tropic HIV Infected Patients

Inclusion Criteria: Asymptomatic HIV-1 infected individuals that are treatmen naïve (ie less than 2 weeks prior ARV exposure) or treatment experienced subjects who are not currently on HAART and have not received any ARVs for 3 months prior to Screening. * Males between 18 years and 65 years of age, utilizing adequate contraceptive methods. * Post menopausal or surgically sterile females between 18 years and 65 years of age. Women of childbearing potential, utilizing adequate contraceptive methods. * CD4-lymphocyte count \>350 cells/mm3 * HIV-1 RNA copies/ml \> 10,000. * HIV-1 is CCR5 tropic virus only. * CCR5 antagonist treatment naive. * BMI \> 16 to \< 32 kg/m2. * Have no clinically significant findings on screening evaluations, which in the opinion of the Investigator would interfere with the subject's ability to comply with the protocol. * Able to comprehend and willing to sign an Informed Consent Form. Exclusion Criteria: * Current or recent (\<30 days) opportunistic infection. * Presence of CXCR4- or dual-tropic HIV-1 virus at Screening or Baseline assessments. * Subjects with chronic renal insufficiency * Personal history of cardiac diseases. * History or presence of an abnormal ECG. * History of unstable ischemic heart disease or uncontrolled hypertension. * History of malignancy, with the exception of cured basal cell or squamous cell carcinoma of the skin. * Subjects who have received radiation therapy or cytotoxic chemotherapeutic agents and have not recovered from side effects. * Current treatment or treatment within 30 days or 5 half-lives with another investigational medication or current enrollment in another investigational drug protocol. * Subjects with unstable medical condition (s), which , in the opinion of the Investigator would compromise their participation in the trial